PMID- 21303751
OWN - NLM
STAT- MEDLINE
DCOM- 20110609
LR  - 20151119
IS  - 1973-9478 (Electronic)
IS  - 1120-009X (Linking)
VI  - 22
IP  - 6
DP  - 2010 Dec
TI  - Weekly regimen of paclitaxel and carboplatin as first-line chemotherapy in 
      elderly patients with stage IIIB-IV non small cell lung cancer (NSCLC): results 
      of a phase II study.
PG  - 419-23
AB  - Single-agent chemotherapy is the preferred treatment option in chemonaive elderly 
      patients with advanced nonsmall-cell lung cancer (NSCLC). The role of combination 
      chemotherapy in this setting is uncertain although several studies report 
      satisfactory efficacy and safety using weekly paclitaxel and carboplatin (AUC=6) 
      as first-line chemotherapy in elderly patients. It is still unclear which 
      schedule of this regimen which could offer the best therapeutic index. The aim of 
      this study was to evaluate the activity and tolerability of concomitant weekly 
      administration of paclitaxel and carboplatin in untreated elderly patients with 
      advanced NSCLC. From february 2005 to April 2008 36 consecutive elderly patients 
      with advanced NSCLC were enrolled. Median age was 74 years (range, 70-83 years) 
      and median ECOG PS was 1 (range, 0-1). patients received carboplatin (AUC=2) and 
      paclitaxel 80 mg/m(2) on days 1,8 and 15 every 28 days. All patients were evaluable 
      for efficacy and toxicity; a median of 4 cycles was administered. Twelve patients 
      had partial response (33%; 95% C.I. 15,8-52,3%), 10 patients (28%) showed stable 
      disease. The median time to progression (TTP) was 5.7 months (95% C.I. 3.1-8.6 
      months) with a median overall survival (MOS) of 9 months (95% C.I. 4.4-13.9 
      months). Toxicity was mild with no cases of febrile neutropenia; 5 patients (14%) 
      developed grade 2 neuropathy. Our study confirms the substantial activity of 
      weekly regimen of paclitaxel and carboplatin. Due to its favorable profile of 
      toxicity this schedule could represent an interesting therapeutic option in 
      selected chemonaive elderly patients with advanced NSCLC.
FAU - Rozzi, A
AU  - Rozzi A
AD  - Clinical Oncology Unit, Istituto Neurotraumatologico Italiano, Grottaferrata 
      (Rome), Italy. antoniorozzi@virgilio.it
FAU - Nardoni, C
AU  - Nardoni C
FAU - Corona, M
AU  - Corona M
FAU - Restuccia, M R
AU  - Restuccia MR
FAU - Falbo, T
AU  - Falbo T
FAU - Lanzetta, G
AU  - Lanzetta G
LA  - eng
PT  - Clinical Trial, Phase II
PT  - Journal Article
PL  - England
TA  - J Chemother
JT  - Journal of chemotherapy (Florence, Italy)
JID - 8907348
RN  - BG3F62OND5 (Carboplatin)
RN  - P88XT4IS4D (Paclitaxel)
SB  - IM
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use
MH  - Carboplatin/administration & dosage/adverse effects
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology
MH  - Disease Progression
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/pathology
MH  - Male
MH  - Neoplasm Staging
MH  - Paclitaxel/administration & dosage/adverse effects
MH  - Survival Rate
MH  - Treatment Outcome
EDAT- 2011/02/10 06:00
MHDA- 2011/06/10 06:00
CRDT- 2011/02/10 06:00
PHST- 2011/02/10 06:00 [entrez]
PHST- 2011/02/10 06:00 [pubmed]
PHST- 2011/06/10 06:00 [medline]
AID - 10.1179/joc.2010.22.6.419 [doi]
PST - ppublish
SO  - J Chemother. 2010 Dec;22(6):419-23. doi: 10.1179/joc.2010.22.6.419.